Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (31-40 of 236) with videos related to

Pageof 24
Sort By:
Scientific American|April 16, 2016
Germ WarfareMaria-Luisa Alegre, Thomas F Gajewski
Science (New York, N.Y.)|August 22, 2020
Immunotherapy with a stingThomas F Gajewski, Emily F Higgs
Biorxiv : the Preprint Server for Biology|April 22, 2024
Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulationEmily F Higgs, Thomas F Gajewski
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2017
The Microbiota: A New Variable Impacting Cancer Treatment OutcomesJessica L Fessler, Thomas F Gajewski
Immunologic Research|March 22, 2005
Metabolic mechanisms of tumor resistance to T cell effector functionCandace M Cham, Thomas F Gajewski
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2005
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cellsCandace M Cham, Thomas F Gajewski
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2005
Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cellsJames P O'Keefe, Thomas F Gajewski
British Journal of Cancer|January 24, 2018
Back from the dead: TIL apoptosis in cancer immune evasionBrendan L Horton, Thomas F Gajewski
The Journal of Experimental Medicine|July 23, 2020
cDC1 dysregulation in cancer: An opportunity for interventionThomas F Gajewski, Kyle R Cron
Nature|May 14, 2015
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityStefani Spranger, Riyue Bao, Thomas F Gajewski
Pageof 24

Showing results (31-40 of 236) with videos related to

Sort By:
Pageof 24
Scientific American|April 16, 2016
Germ WarfareMaria-Luisa Alegre, Thomas F Gajewski
Science (New York, N.Y.)|August 22, 2020
Immunotherapy with a stingThomas F Gajewski, Emily F Higgs
Biorxiv : the Preprint Server for Biology|April 22, 2024
Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulationEmily F Higgs, Thomas F Gajewski
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2017
The Microbiota: A New Variable Impacting Cancer Treatment OutcomesJessica L Fessler, Thomas F Gajewski
Immunologic Research|March 22, 2005
Metabolic mechanisms of tumor resistance to T cell effector functionCandace M Cham, Thomas F Gajewski
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2005
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cellsCandace M Cham, Thomas F Gajewski
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2005
Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cellsJames P O'Keefe, Thomas F Gajewski
British Journal of Cancer|January 24, 2018
Back from the dead: TIL apoptosis in cancer immune evasionBrendan L Horton, Thomas F Gajewski
The Journal of Experimental Medicine|July 23, 2020
cDC1 dysregulation in cancer: An opportunity for interventionThomas F Gajewski, Kyle R Cron
Nature|May 14, 2015
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityStefani Spranger, Riyue Bao, Thomas F Gajewski
Pageof 24